Subject: Big News Day from MJNA Subsidiaries Kannalife and HempMeds Brasil

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Big News Day from MJNA Subsidiaries Kannalife and HempMeds Brasil
Hot Stock to WatchHot Stock to Watch

Company: Medical Marijuana, Inc. (Pink Sheets: MJNA)


Price: 0.0802

Change (%): - 0.0001 (0.12)

Volume: 874,668
MJNA Chart

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil To Sponsor 8th ABN-RJ/ANERJ Congress in Rio de Janeiro

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ - Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is proud to sponsor the 8th Brazilian Academy of Neurology/Association of Neurology of the State of Rio de Janeiro (ABN-RJ/ANERJ) Congress Workshops taking place from September 28-30 at the Windsor Barra Convention Center in Rio De Janeiro, Brazil.

The 8th ABN-RJ/ANERJ Congress aims to bring together professionals working in Neurology/Neurosciences and related fields to deepen the scientific debate and the development of knowledge in leading areas such as neurogenetics, neuroimaging, neuroimmunology, translational neurology, among others.

Continue Reading

FOX Business' Varney & Co. Set to Feature Medical Marijuana, Inc. Portfolio Company Kannalife's NFL Spokesman Nick Lowery on CTE

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ - Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that Nick Lowery, new NFL spokesman for portfolio company Kannalife Sciences, will be interviewing on FOX Business’ Varney & Co. Tuesday, Sept. 26, at 9:15 a.m. ET. He will be speaking about his work with Kannalife and current research about Chronic Traumatic Encephalopathy (CTE).

CTE is a degenerative neurological disease caused by repeated head trauma and is only diagnosed with certainty in post-mortem examinations. CTE can lead to symptoms like violent mood swings, depression and other cognitive difficulties. The evidence of severe CTE was seen last week in the latest brain autopsy of NFL player and New England Patriots Tight-End Aaron Hernandez. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Since not much is known about this debilitating disease, treatment and prevention options are currently bleak, while interesting research options are on the horizon.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks